Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217
Vojtech Parrák, Stanislav Katina, Nicholas Cullen, Eva Kontseková et al.
Citations
13 citations
Journal
Alzheimer s Research & Therapy
Topics
Alzheimer's disease research and treatments
Field-Weighted Citation Impact (FWCI)
4.25
article
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217
Vojtech Parrák, Stanislav Katina, Nicholas Cullen, Eva Kontseková, Branislav Kováčech, Erik Stoops, Jozef Hanes, Howard Feldman, Jeroen Vanbrabant, Michal Fresser, Norbert Žilka, Eugeen Vanmechelen, Bengt Winblad, Petr Novák
article en
13 citations
Abstract
No abstract available for this paper.
Publication Tag
Alzheimer s Research & TherapyVol. 16(1)
Institutions
Ablynx (Belgium) (BE), Karolinska University Hospital (SE), Lund University (SE), Slovak Academy of Sciences (SK), Masaryk University (CZ), Karolinska Institutet (SE), University of California San Diego (US), AXON Neuroscience (Cyprus) (CY), Institute of Neuroimmunology of the Slovak Academy of Sciences (SK), AXON Neuroscience (Slovakia) (SK), ADx NeuroSciences